The Foundation for Prader-Willi Research

Founded in 2017, Aardvark Therapeutics is a biopharmaceutical company dedicated to developing small molecule therapeutics targeting metabolic diseases. Its lead product candidate, ARD-101, is an oral gut-restricted therapy designed to selectively activate bitter taste receptors for hunger-associated conditions.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

Founded in 2017, Aardvark Therapeutics is a biopharmaceutical company dedicated to developing small molecule therapeutics targeting metabolic diseases. Its lead product candidate, ARD-101, is an oral gut-restricted therapy designed to selectively activate bitter taste receptors for hunger-associated conditions.

Beryl Therapeutics goal is to open up a new frontier in bone health based on the revelation that lipids are crucial signaling molecules that play a role in bone mass regulation. Beryl is developing a patented first-in-class small molecule to increase peak bone mass and cure poor bone mineral density caused by disease or natural aging.

Founded in 2018, Lipidio Pharmaceuticals is a biopharmaceutical company based in San Diego, California. It focuses on developing and manufacturing drugs to treat diseases associated with excess body fat, such as Prader Willi syndrome, nonalcoholic steatohepatitis (NASH), and obesity-related conditions.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.